Press release
Hypoxia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen
To Know in detail about the Hypoxia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoxia Market Forecast [https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Hypoxia Market Report:
*
The Hypoxia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In November 2024, Movano Health Inc. (Nasdaq: MOVE) announced the successful testing of its newly developed blood pressure wrist wearable during a hypoxia clinical trial conducted on November 5th and 6th at the University of California, San Francisco. The updated device incorporates 12 additional mmWave antennas, enhancing data collection while minimizing the impact of placement. Featuring a slimmer and more comfortable design, the wearable also tracks multiple vital signs, including pulse rate, blood oxygen saturation (SpO2), respiration rate, and ECG waveforms, offering a comprehensive health monitoring solution.
*
According to Biogen's 2022 data, approximately two million individuals are projected to experience a stroke annually in both the United States and the European Union.
*
According to a study led by Myriam Lacerte et al. (2020), the incidence rates of Hypoxic Brain Injury are estimated to be around 50 per 100,000 population, with survival-to-discharge rates at approximately 8%. This translates to over 10,000 patients per year in the United States alone.
*
Key Hypoxia Companies: Keros Therapeutics, Inc., Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others
*
Key Hypoxia Therapies: RKER-012, Trans Sodium Crocetinate, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others
*
The Hypoxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxia pipeline products will significantly revolutionize the Hypoxia market dynamics.
Hypoxia Overview
Hypoxia refers to a condition where there is a deficiency in the amount of oxygen reaching the body's tissues. This can occur when the oxygen supply to tissues is insufficient, leading to inadequate oxygenation of cells. Hypoxia can be caused by various factors, including low oxygen levels in the environment (such as at high altitudes), respiratory conditions that impair oxygen uptake by the lungs, cardiovascular disorders that reduce oxygen delivery to tissues, anemia (reduced oxygen-carrying capacity of the blood), or conditions that impair oxygen utilization by cells.
Get a Free sample for the Hypoxia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hypoxia-market [https://www.delveinsight.com/report-store/hypoxia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypoxia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypoxia Epidemiology Segmentation:
The Hypoxia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Hypoxia
*
Prevalent Cases of Hypoxia by severity
*
Gender-specific Prevalence of Hypoxia
*
Diagnosed Cases of Episodic and Chronic Hypoxia
Download the report to understand which factors are driving Hypoxia epidemiology trends @ Hypoxia Epidemiology Forecast [https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypoxia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoxia market or expected to get launched during the study period. The analysis covers Hypoxia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypoxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypoxia Therapies and Key Companies
*
RKER-012: Keros Therapeutics, Inc.
*
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
*
Rejuveinix: Reven Pharmaceuticals
*
RLS-0071: ReAlta Life Sciences, Inc
*
Sargramostim: Partner Therapeutics, Inc
*
Tirapazamine: Teclison Ltd.
*
Belzutifan: Merck Sharp & Dohme
*
Tirzepatide: Eli Lilly and Company
*
TMS-007: Biogen
*
Aes-103: AesRx, LLC
*
TH-302: Threshold Pharmaceuticals
*
GSK2256294: GlaxoSmithKline
*
RO7070179: Roche
*
GBT440: Global Blood Therapeutics
*
AKB-6548: Akebia Therapeutics
Discover more about therapies set to grab major Hypoxia market share @ Hypoxia Treatment Landscape [https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypoxia Pipeline Market Drivers
*
Increase in prevalence of Hypoxia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Hypoxia Market.
Scope of the Hypoxia Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Hypoxia Companies: Keros Therapeutics, Inc., Diffusion Pharmaceuticals, Reven Pharmaceuticals, ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others
*
Key Hypoxia Therapies: RKER-012, Trans Sodium Crocetinate, Rejuveinix, RLS-0071, Sargramostim, Tirapazamine, Belzutifan, Tirzepatide, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others
*
Hypoxia Therapeutic Assessment: Hypoxia current marketed and Hypoxia emerging therapies
*
Hypoxia Market Dynamics: Hypoxia market drivers and Hypoxia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Hypoxia Unmet Needs, KOL's views, Analyst's views, Hypoxia Market Access and Reimbursement
To know more about Hypoxia companies working in the treatment market, visit @ Hypoxia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypoxia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hypoxia Market Report Introduction
2. Executive Summary for Hypoxia
3. SWOT analysis of Hypoxia
4. Hypoxia Patient Share (%) Overview at a Glance
5. Hypoxia Market Overview at a Glance
6. Hypoxia Disease Background and Overview
7. Hypoxia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoxia
9. Hypoxia Current Treatment and Medical Practices
10. Hypoxia Unmet Needs
11. Hypoxia Emerging Therapies
12. Hypoxia Market Outlook
13. Country-Wise Hypoxia Market Analysis (2019-2032)
14. Hypoxia Market Access and Reimbursement of Therapies
15. Hypoxia Market Drivers
16. Hypoxia Market Barriers
17. Hypoxia Appendix
18. Hypoxia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoxia-market-predicted-to-see-upsurge-through-2032-highlights-delveinsight-realta-life-sciences-inc-partner-therapeutics-inc-teclison-ltd-merck-sharp-dohme-eli-lilly-and-company-biogen]
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypoxia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | ReAlta Life Sciences, Inc, Partner Therapeutics, Inc, Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Biogen here
News-ID: 3881365 • Views: …
More Releases from ABNewswire
Full Body Checkup The Gateway to Proactive Health
A full body checkup is one of the most thorough and proactive approaches to taking control of your long-term health. By regularly evaluating all major bodily systems and risk factors, a full body checkup helps to identify potential problems before symptoms develop, granting you the opportunity to stay healthy and empowered. At Liv Hospital [https://int.livhospital.com/], patients benefit from advanced diagnostics, experienced specialists, and patient-centered comfort throughout the process, making routine…
Andy DeFrancesco on Market Cycles, Business Mindset, and the Future of the Busin …
Image: https://www.abnewswire.com/upload/2025/11/d35dbae4dbd114c90cd75748c7d93c3c.jpg
Market optimism rises and falls in waves, but the people who shape industries rarely move with emotion. They study patterns, look beyond the noise, and respond to momentum before the crowd recognizes it. Andy DeFrancesco [https://www.linkedin.com/authwall?trk=bf&trkInfo=AQGgt6lQ4W3QHgAAAZqcxvlI_dUN8oxVB90MzEZ8iE-RruFwmtW1mgWieTjNpqt9TfGmpIboUWLMgp2cCS3U44ppQA-fyWs0h6Op-uvqdNuDq7e6HJhMneocPYkXhKrOLhPDFUM=&original_referer=&sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fandy-defrancesco-77584930a] has spent his entire career doing exactly that. After decades in public markets, private equity, and emerging sectors, he has learned that the numbers matter - but the psychology behind them matters more.
Business…
The Current Business Landscape: A High-Stakes, Tech-Driven Era
In 2025, the global business environment is shaped by a complex interplay of technology, economic pressures, and evolving market expectations. While inflation and cost control remain real concerns for many companies, digital transformation and cyber risk are dominating boardroom conversations. Business leaders increasingly cite artificial intelligence, cybersecurity, and cost management as their top priorities.
At the same time, the pace of technology adoption continues to accelerate. Small and midsize businesses are…
Contrarian Watch Company Launches Swiss-Made Luxury Timepieces for Those Who Dar …
Contrarian Watch Company debuts with a mission to redefine accessible luxury through Swiss-made timepieces that blend precision craftsmanship with bold design. The collection targets individuals who refuse to follow trends, offering top-quality watches that make statements this holiday season and beyond.
As holiday shopping season begins and consumers seek meaningful gifts that convey sophistication and thought, a new player in the luxury watch market is challenging industry conventions. Contrarian Watch Company…
More Releases for Hypoxia
Hypoxia Inducible Factor Alpha inhibitor Market Global Rising Demand & Huge Scop …
The global Hypoxia Inducible Factor Alpha Inhibitor market is projected to reach approximately USD 1.12 billion by 2033, growing at a CAGR of 10.3% from 2024 to 2033.
Hypoxia Inducible Factor Alpha inhibitor Market Overview
The Hypoxia Inducible Factor Alpha (HIF-α) Inhibitor market is witnessing rapid growth driven by its critical role in treating cancers and other hypoxia-related diseases. Increasing research on the molecular pathways involving HIF-α has led to the development…
Hypoxia Market | Analysis by Industry Trends, Size, Share, Company Overview, Gro …
The higher A comprehensive understanding of the strategic study of partnerships, acquisitions, mergers, expansions, and investments is provided by the Hypoxia Market Research Report. Businesses can benefit from the market research analysis and data in this study when planning their production, product launches, costs, inventories, purchases, and marketing activities. This object-oriented market research report was created by combining the best talent solutions, industry insight, industry expertise, and the newest techniques and…
Hypoxia Treatment Market Size Share Growth Opportunities and Forecast 2023-2030
Global Hypoxia Treatment Market Surges to US$ 77.6 Million in 2022, Projected to Reach US$ 134.3 Million by 2030 with a 7.2% CAGR
The global hypoxia treatment market demonstrated remarkable growth in 2022, reaching a valuation of US$ 77.6 million. Forecasts for the period from 2023 to 2030 suggest a robust upward trajectory, with an anticipated market value of US$ 134.3 million, reflecting a Compound Annual Growth Rate (CAGR) of 7.2%.
Hypoxia,…
Hypoxia Market Drivers, Industry Threats, and Opportunities By 2028
Data Bridge Market Research analyses that the hypoxia will exhibit a CAGR of around 7.50% for the forecast period of 2021-2028.
A few of the most important objectives of the world class Hypoxia report include; study and forecast the market size in the worldwide market. As well, it defines, explains and forecasts the market by various segments such as type, application, end-use, and region. The report also studies and compares the…
Hypoxia Market is Projected to Grow During the Forecast Period 2022-2032 - Estim …
The Hypoxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxia pipeline products will significantly revolutionize the Hypoxia market dynamics.
DelveInsight's "Hypoxia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypoxia, historical and forecasted epidemiology as well as the Hypoxia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Hypoxia Chamber Market to Register Steady Growth During 2031
Hypoxia Chamber Market: Overview
The hypoxia chamber market has made strides on the back of the growing application of these in cell culture studies. They are utilized in regulating the oxygen levels through control of hypoxia in cell culture in vitro. Over the years, the hypoxia chamber market has seen new avenues from the rise in demand in various animal studies and cell research studies. In recent years, the use of…
